Gene · 4102
Papers3,353
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 3,353
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Investigation and validation of prognostic features associated with transient receptor potential channel genes in gastric cancer. | PeerJ | 2026 | 42602890 | PubTator, text mining | PubMed |
iPSC-derived polyvalent vaccines as ontogenetically informed immunogens toward overcoming immune refractoriness in microsatellite-stable colorectal cancer: An emerging frontier in cancer immunotherapy. | Mol Immunol | 2026 | 42594762 | PubTator, text mining | PubMed |
| AI-enabled virtual immunopeptidomics links quantitative neoantigen presentation to immunogenicity. | bioRxiv | 2026 | 42146452 | PubTator, text mining | PubMed |
| A Pan-Cancer Transcriptomic Signature for Conserved Molecular Programs Underlying Premalignant-Malignant Progression Across Common Carcinomas. | Dent J (Basel) | 2026 | 42041682 | PubTator, text mining | PubMed |
| Mechanisms of Polymer-Antigen Binding and Hydrolysis Inhibition: Molecular Dynamics Simulations and Experimental Measurements. | Polymers (Basel) | 2026 | 41977530 | PubTator, text mining | PubMed |
| Non-Invasive Urine-Based Diagnostic Technologies for Early Bladder Cancer. | Biosensors (Basel) | 2026 | 41892063 | PubTator, text mining | PubMed |
| Identification and evaluation of tumor pyroptosis-associated antigens for design a vaccine candidate against lung cancer. | Sci Rep | 2026 | 41857073 | PubTator, text mining | PubMed |
| Overcoming T cell tolerance to tumor self-antigens through catch-bond engineering. | Science | 2026 | 41855322 | PubTator, text mining | PubMed |
| Phase Ib multicenter study of anti-TIM-3 (S095018/Sym023) in combination with anti-PD-1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer. | J Immunother Cancer | 2026 | 41825935 | PubTator, text mining | PubMed |
| Antibody screening for tumor and immune hotspot targets: The frontier of new methods and technologies. | J Pharm Anal | 2026 | 41798069 | PubTator, text mining | PubMed |
| Spontaneous remission of congenital acute megakaryoblastic leukemia in a neonate with down syndrome. | Open Med (Wars) | 2026 | 41767736 | PubTator, text mining | PubMed |
| PROTAC-based protein degradation: a window of opportunity for melanoma therapy. | J Biomed Sci | 2026 | 41761284 | PubTator, text mining | PubMed |
| Exploring high-affinity MAGE-A3-specific T-cell receptors derived from healthy donor PBMCs: A preclinical evaluation. | Transl Res | 2026 | 41759780 | PubTator, text mining | PubMed |
| Cross-Species Upregulation of MAGED2 in Liver Cancer Suggests a Role in Obesity-Driven Tumor Progression. | Curr Issues Mol Biol | 2026 | 41751403 | PubTator, text mining | PubMed |
| Harnessing Vaccines in the Treatment of Solid Tumors: Advances, Challenges, and Future Directions. | Vaccines (Basel) | 2026 | 41746058 | PubTator, text mining | PubMed |
| mRNA and Peptide Vaccines in Melanoma-Current Landscape and Future Direction. | Cells | 2026 | 41744786 | PubTator, text mining | PubMed |
| Ready or not, here they come: a practical guide to adoptive T-cell therapies for solid tumors for medical oncologists. | Oncologist | 2026 | 41739670 | PubTator, text mining | PubMed |
| Nanomedicine Meets Immunotherapy: Transforming Chimeric Antigen Receptor T Cell Treatment for Solid Tumors. | Small Sci | 2026 | 41737839 | PubTator, text mining | PubMed |
| Reprogramming the immune microenvironment in triple-negative breast cancer with mRNA therapeutics. | Cancer Lett | 2026 | 41730382 | PubTator, text mining | PubMed |
| Synergistic effects of radiotherapy and immunotherapy: improving oncological outcomes. | Front Immunol | 2026 | 41716387 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4102/papers